The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
Open accessAbstract
Purpose: Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conducted to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors. Patients and Methods: Patients enrolled to intermittent dosing cohorts received navitoclax on day −3, followed by dosing on days 1 to 14 of a 21-day cycle. Patients on continuous dosing received a 1-week lead-in dose of 150 mg followed by continuous daily administration. Blood samples were collected for pharmacokinetic analyses, biomarker analyses, and platelet monitoring. Results: Forty-seven patients, including 29 with small-cell lung cancer (SCLC) or pulmonary carcinoid, were enrolled between 2007 and 2008, 35 on intermittent and 12 on continuous dosing cohorts. Primary toxicities included diarrhea (40%), nausea (34%), vomiting (36%), and fatigue (34%); most were grade 1 or 2. Dose- and schedule-dependent thrombocytopenia was seen in all patients. One patient with SCLC had a confirmed partial response lasting longer than 2 years, and eight patients with SCLC or carcinoid had stable disease (one remained on study for 13 months). Pro-gastrin releasing peptide (pro-GRP) was identified as a surrogate marker of Bcl-2 amplification and changes correlated with changes in tumor volume. Conclusion: Navitoclax is safe and well tolerated, with dose-dependent thrombocytopenia as the major adverse effect. Preliminary efficacy data are encouraging in SCLC. Efficacy in SCLC and the utility of pro-GRP as a marker of treatment response will be further evaluated in phase II studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“clinical trial data suggest that the dose-limiting toxicities of obatoclax may preclude sufficient target inhibition, in contrast to ABT-263 (30, 34, 35).”
From mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1 (2014) · cites this paper as [30]
Experimental — accuracy not yet measuredIn the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.a115.109006 · Cited by 153
RetractedPardo, O. E., Arcaro, A., Salerno, G., Raguz, S., Downward, J., & Seckl, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109006200 · Cited by 145
RetractedAn inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031 · cited 1×
“This is a mechanism-based toxicity induced by inhibition of Bcl-xL in circulating platelets,(13,18) which is required for platelet survival.(19,20) Here we describe a phase I dose-escalation study to evaluate the safety (with particular attention to platelet dynamics), pharmacokinetics, and preliminary efficacy of nav…”
BackgroundThe role of Bcl-2 family members in tumorigenesis
Kirkin, V., Joos, S., & Zörnig, M. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2003.08.009 · Cited by 567
Some practical improvements in the continual reassessment method for phase I studies
Goodman, S. N., ZAHURAK, M. L., & Piantadosi, S. (1995) · Statistics in Medicine · doi:10.1002/sim.4780141102 · Cited by 475
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Research works printed but not linked: 2
- Ben-Ezra JM, 1994, Am J Pathol, 145, 1036
- Brambilla E, 1996, Am J Pathol, 149, 1941
Cited by
Sorted by citations
Items 501–600 of 616
Zhou, Y., Li, K., Li, F., Han, S., Wang, Y., Li, X., & Zhan, Y. (2019) · Journal of Nanomaterials · doi:10.1155/2019/5274598 · Cited by 3
Hisam, N. S. N., Ugusman, A., Rajab, N. F., Gregoli, K. D., Ahmad, M. F., & Anuar, N. N. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2759691/v1 · Cited by 3
Molecular Pharmacological Interventions for Endometrial Cancer: A Comprehensive Review
Qin, W., Qi, Y., Li, Q., Wang, B., Wang, J., Ge, X., Li, Y., Zhang, X., & Liu, K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s524181 · Cited by 2
Christoff, M., Szczepańska, A., Jakubowicz-Gil, J., & Zając, A. (2025) · Cells · doi:10.3390/cells15010053 · Cited by 2
Targeting BCL-XL for degradation synergizes with gemcitabine against cholangiocarcinoma
Zeng, Q., Zhang, Y., Yang, Y., Liu, X., Dong, X., Pan, Y., Hu, L., Zhang, A., Yang, J., Luo, Q., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04671-9 · Cited by 2
Chitale, A., Verma, S., & Mugale, M. N. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70203 · Cited by 2
Molecular Biology and Genetics of Lung Cancer
Milanović, D. (2011) · Medical radiology · doi:10.1007/174_2011_310 · Cited by 2
Therapeutics targeting BCL2 family proteins
Dai, H., Meng, X. W., Ye, K., Jia, J., & Kaufmann, S. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814208-0.00007-5 · Cited by 2
Cytokeratin 18 (CK18) and Caspase-Cleaved CK18 (ccCK18) as Response Markers in Anticancer Therapy
Hamilton, G. (2012) · InTech eBooks · doi:10.5772/39194 · Cited by 2
ASAKAWA, T., Ishizuka, N., & Hamada, C. (2012) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.43.21 · Cited by 2
Crystallization of interleukin-18 for structure-based inhibitor design
Krumm, B., Meng, X., Xiang, Y., & Deng, J. (2015) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x15006871 · Cited by 2
Kamath, P. R., Joseph, M. M., Salam, A. A. A., Therakathinal, S. T., Sunil, D., Biswas, S., & Pai, K. S. R. (2017) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.21962 · Cited by 2
RetractedYin, Z., Yang, D., Wang, J., & Jiang, Y. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817666200213114759 · Cited by 2
Tafuri, A., Milella, M., Iacovelli, S., De, F., Gregorj, C., Bergamo, P., Miele, A., Licchetta, R., Konopleva, M. Y., James, A., et al. (2011) · InTech eBooks · doi:10.5772/28114 · Cited by 2
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
Fennell, D. A., & Swanton, C. (2012) · The EPMA Journal · doi:10.1186/1878-5085-3-6 · Cited by 2
Other Nonbiological Approaches to Targeted Cancer Chemotherapy
Avendaño, C., & Menéndez, J. C. (2015) · Elsevier eBooks · doi:10.1016/b978-0-444-62649-3.00011-9 · Cited by 2
Broadening the horizon: The promise of PROTACs in non-malignant disorders
Fu, L., Zeng, G., Cao, Y., He, Y., Zhao, Y., Tian, C., Chen, J., Feng, H., Xi, J., Shao, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118586 · Cited by 1
Zhou, Q., Nguyen, T. T. T., Angelastro, J. M., Siegelin, M. D., & Greene, L. A. (2026) · Cells · doi:10.3390/cells15090826 · Cited by 1
Sze, L.-P., Ho, V. M.-K., Fung, W.-K. W., Law, K.-H., Tu, Y., So, Y.-H., Chung, S.-F., Wong, W., Liu, Z., Shum, A. S. W., et al. (2026) · Cells · doi:10.3390/cells15020164 · Cited by 1
Bozhdansky, V., Tayar, S., Kashkash, S., Bacharach, E., & Ehrlich, M. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02823-1 · Cited by 1
Hematopoietic stem cell senescence and opportunities for intervention
Barve, A., Dabas, P., Cain, T. L., & McKinney‐Freeman, S. (2026) · Experimental Hematology · doi:10.1016/j.exphem.2026.105425 · Cited by 1
Chen, E. C., Liu, Y., Bell, H. L., Ryan, J. A., Wu, J., Minihane, E., Luskin, M. R., Winer, E. S., Vedula, R. S., Volpe, V. O., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4905 · Cited by 1
Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective
Bisi, N., & Hamzé, A. (2026) · Pharmaceuticals · doi:10.3390/ph19081146 · Cited by 1
Bcl-2 Family Proteins in Development and Treatment of Malignant Diseases
Račay, P., Jurečeková, J., Štefaniková, A., Kliková, K., Hatok, J., & Dobrota, D. (2011) · Acta Medica Martiniana · doi:10.2478/v10201-011-0018-4 · Cited by 1
Apoptotic Pathway Manipulation
Camidge, D. R., & Thorburn, A. M. (2011) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000407571.60325.8c · Cited by 1
Self-citationSensitivity and Resistance to BH3 Mimetics in Cancer Therapy
Floros, K. V., Faber, A. C., & Harada, H. (2018) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-67932-7_7 · Cited by 1
Disrupting Protein–Protein Interfaces Using GRID Molecular Interaction Fields
Cross, S., Baroni, M., Ortuso, F., Alcaro, S., & Cruciani, G. (2013) · Springer eBooks · doi:10.1007/978-3-642-37999-4_3 · Cited by 1
Bcl-2 Family: Translational Aspects
Bose, P., & Grant, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1393-0_4 · Cited by 1
Drug Discovery by Targeting Protein–Protein Interactions
Bettinetti, L., Magnani, M., & Padova, A. (2013) · Springer eBooks · doi:10.1007/978-3-642-37999-4_1 · Cited by 1
Novel Therapeutic Strategies for Pancreatic Cancer
Quinn, B. A. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/t39h-kj31 · Cited by 1
Discovery and Chemical Development of S 44563, a Dual Bcl-2/Bcl-xL Inhibitor
Hardouin, C., & Starck, J.-B. (2020) · ACS symposium series · doi:10.1021/bk-2020-1369.ch006 · Cited by 1
B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
Oliveira, R. C., Gama, J. M., & Casanova, J. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00154 · Cited by 1
Reynoso, D. (2012) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Chemical library screening approaches to aid the design of protein–protein inhibitors
Laraia, L., & Spring, D. R. (2013) · doi:10.4155/ebo.13.151 · Cited by 1
Smirnov, P., Nair, S. K., Aghababazadeh, F. A., Feizi, N., Smith, I., Pugh, T. J., & Haibe‐Kains, B. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.22.513279 · Cited by 1
Pharmacologic Features of Drugs Targeting BCL 2 Family Members
Lue, J. K., & O’Connor, O. A. (2023) · Wiley eBooks · doi:10.1002/9781119819950.ch11 · Cited by 1
Novel Therapeutic Targets in Soft Tissue Sarcomas
Quincy, S. C., & Karen, E. P. (2011) · InTech eBooks · doi:10.5772/27522
Mitochondria : a target for anticancer therapy
Kruspig, B. (2014) · Figshare
Development of effective anti-cancer agents targeting drug-resistant malignancies
Das, S. G. (2011) · University of Minnesota Digital Conservancy (University of Minnesota)
BH3-Only Proteins in Cancer and Apoptosis
Ghiotto, F., Tenca, C., Fais, F., & Bruno, S. (2013) · Springer eBooks · doi:10.1007/978-94-007-6211-4_9
Small-Cell Lung Cancer: State-of-the-Art Treatment
Rossi, A. (2012) · Lung Cancer Management · doi:10.2217/lmt.12.1
Immunohistochemistry in the Study of Cancer Biomarkers for Oncology Drug Development
Jiang, F., & McKeegan, E. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-1516-3_5
Self-citationLeading Small Molecule Inhibitors of Anti-Apoptotic Bcl-2 Family Members
Yazbeck, V. Y., & Johnson, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_9
The Role of BCL-2 Family in Clinical Response of Chronic Lymphocytic Leukemia
Al-harbi, S. (2012) · OhioLink ETD Center (Ohio Library and Information Network)
Treatment of small cell lung cancer
Aleksic, A., & Popat, S. (2012) · Informa Healthcare eBooks · doi:10.3109/9781841848679.012
Regulation of Megakaryocyte and Platelet Survival
Au, A. E., Lebois, M., Pleines, I., & Josefsson, E. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-39562-3_9
The genetics and kinetics of BCL2 driven lymphoid malignancies
Webster, P. (2014) · Spiral (Imperial College London) · doi:10.25560/45406
FATE1: Contributor to Tumor Cell Fitness and Example of an Oncogene-Activated Cancer Testis Antigen
Taus, P. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/6ww8-8048
Characterizing the Mechanism of Cul7-mediated Inhibition of Cell Death
Oliveri, S. (2011) · TSpace (University of Toronto)
Molecular assessment of the cellular origin of Merkel cell carcinoma
Chteinberg, E. (2020) · doi:10.26481/dis.20201120ec
Understanding and drugging the Bcl-2 transmembrane interactome for tumor treatment
Lucendo, E. (2020) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/155914
Pan, X., Tan, J., Du, R., Jiang, Y., Weng, Y., & Zhou, D. (2020) · doi:10.21203/rs.3.rs-25599/v1
Insights into Novel Drugs Targeting Bcl-2 protein as Potential Anti-cancer Agents
Darwish, K. M. (2021) · Records of Pharmaceutical and Biomedical Sciences/Records of Pharmaceutical & Biomedical Sciences · doi:10.21608/rpbs.2020.30507.1064
Atangcho, L. (2020) · Deep Blue (University of Michigan)
Small Cell Lung Cancer: Biology Advances
Hann, C. L. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_9
Self-citationProstate Cancer Clinical Trials Group - The University of Michigan Site
Hussain, M. (2014) · Defense Technical Information Center (DTIC) · doi:10.21236/ada612883
Gilmore, A. P. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735321996.793566253
Pan, X., Tan, J., Du, R., Jiang, Y., Weng, Y., & Zhou, D. (2020) · doi:10.21203/rs.3.rs-25599/v2
Epithelial-mesenchymal transition and resistance to EGFR inhibitors
Jacob, S., Kurupi, R., & Faber, A. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00009-7
Fang, H., Harned, T. M., Kalous, O., Maldonado, V., DeClerck, Y. A., & Reynolds, C. P. (2023) · doi:10.1158/1078-0432.c.6520070.v1
Balachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2023) · doi:10.1158/1078-0432.c.6529392.v1
Balachander, S. B., Criscione, S. W., Byth, K. F., Cidado, J. R., Adam, A., Lewis, P. M., Macintyre, T., Wen, S., Lawson, D., Burke, K. A., et al. (2023) · doi:10.1158/1078-0432.c.6529392
Hua, F., Harned, T. M., Kalous, O., Maldonado, V., DeClerck, Y. A., & Reynolds, C. P. (2023) · doi:10.1158/1078-0432.c.6520070
Data from Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer
de Paula, B., Kieran, R., Koh, S. S. Y., Crocamo, S., Abdelhay, E. S. F. W., & Muñoz‐Espín, D. (2023) · doi:10.1158/1535-7163.c.6597340.v1
Insights into protein-bound uremic toxins in proximal tubule cell senescence and kidney fibrosis
Yang, Y. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/1996
Liu, P., Ben, H., Guo, J., Pang, L., Liu, N., Wang, Y., Shi, Y., Yang, P., Gao, Y., Guan, Y., et al. (2024) · Microchemical Journal · doi:10.1016/j.microc.2024.110155
BCL2 inhibition: back to the future!
Dyer, M. J. S., & Walter, H. S. (2024) · Blood · doi:10.1182/blood.2023023796
Apoptosis Resistance in Solid Tumours: A Potential Therapeutic Target in Gastric Carcinoma?
Butterworth, W. A., Griffiths, E. A., & Shannon-Lowe, C. D. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_320
Vardon, A., Haston, S., Guiho, R., Carvahlo, D., Carter, R., Boult, J. K. R., Gharai, D., Santhakumar, D., Cloete, I., Gray, J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.20.629607
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms
Sukrithan, V., Ahmed, U., Krause, H. B., Gandhi, N. S., Elliott, A., Hinton, A. C., Walker, P., Vanderwalde, A. M., Zhou, Y. H., Patel, D. C., et al. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0341
ULK1 phosphorylation and cardiomyocyte senescence: molecular nexus in cardiac ageing
Vinci, M. C. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf132
Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein
Zhu, W., He, Y., Chen, G., & Zhu, D. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch12
Ren, C., Leung, G. H. D., Tang, Q., Zhang, P., Ma, Y., Xin, Y., Lok, S. W. Y., Pun, F. W., & Zhavoronkov, A. (2025) · npj Aging · doi:10.1038/s41514-025-00294-1
Brock, K., Homer, V., Soul, G., Potter, C., Chiuzan, C., & Lee, S. (2021) · Figshare · doi:10.6084/m9.figshare.14913431
Akbar, A., Nawaz, S., Iqbal, Q. M., Ashraf, E., Mazhar, M., & Irum, B. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i12.2684
Guiho, R., Hamdi, H., Cooksley, G., Chang, T. H., Cao, L., Sigaud, R., Bliss, S., Vardon, A., Haston, S., Selt, F., et al. (2026) · Neuro-Oncology · doi:10.64898/2026.01.13.698644
Protein-protein interaction inhibitors in cancer
Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4
The combination therapy with venetoclax in therapeutic strategy of acute lymphoblastic leukemia
Shamahmood, M. N., Yousefi, M. J., Miri, A., & Mezginejad, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-04593-1
A proteomic approach for understanding the metabolic adaptations in non-small cell lung cancer
Martín-Bernabé, A. (2018) · theses.fr (ABES) · doi:10.70675/426e7b40z057az4326z8cfez7da3a5c12c7e
Louault, K. (2018) · theses.fr (ABES) · doi:10.70675/0aef1137z5689z4922z8455zdbe4b757612c
Dissecting the impact of cellular senescence on muscle regeneration
Cazin, C. (2020) · theses.fr (ABES) · doi:10.70675/42a7ff38zb338z4eb8za925z2ce0a01ee74e
Mitochondrial metabolism as a pharmacological target for cancer therapeutics
Yu, Y., Ding, W., Liu, S., Glorieux, C., Liu, P., & Huang, P. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100137
Mechanisms of resistance in small cell lung cancer
Yu, W., Zhao, S., Zheng, Z., Kang, R., Sun, C., Liu, H., Wang, H., Y, J., & Yu, J. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004099
Mohiuddin, M. (2026) · Health Science Reports · doi:10.1002/hsr2.72506
Oliveira, M. L., Nuantang, K., Huré, G., Ávila-Ávila, A., Bresson, L., Haumont, S., Kostova, V., Novak, T., Toumelin-Braizat, G. L., Guerlesquin, J., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02998-z
Integrating senotherapeutics into transplantation: liver reconditioning in an aging donor pool
Buch, M. L., Esser, H., Perera, H., Zheng, R., Ferreira-González, S., & Forbes, S. J. (2026) · Transplant International · doi:10.3389/ti.2026.16347
Liu, X., Guo, Y., Popa‐Wagner, A., Lämmermann, I., Grillari, J., & Hermann, D. M. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103206
Wang, J., Xie, T., Jiang, H., Shan, Y., Juengpanich, S., Li, S., Topatana, W., Liu, Y., Wan, H., Qian, Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04733-3
The advancement of Venetoclax in hematological malignancies and solid tumors
Long, C., Zhang, H., Yao, Y., Liu, T., Peng, H., & Sheng, Y. (2026) · Heliyon · doi:10.1016/j.heliyon.2026.e45207
Capece, M., Reshetnikova, E., Wang, Y., Katuwal, N. B., Bellan, D. D. L., Kumar, A., Bharti, V., Watkins, R., Krull, J. E., Gu, S., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013441
Terpenoids as Emerging Senotherapeutics: Mechanistic Insights and Therapeutic Potential
Yi, S., Park, J. Y., & Lee, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156874
Huda, M. N., Afrin, H., Khatun, Z., An, J. M., Lee, Y.-K., & Nurunnabi, M. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00017
Suri, P., Daartey, A. B., Khan, D. M. I. O., Rayana, N. P., Chilamakuri, R., Godugu, D., Azad, M. G., Reeb, K. L., & Richardson, D. R. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100158
Bulbul, M. I. A., Khan, T., Sharid, M. A. G., Shuvo, M. N., Debnath, A. C., Ali, M. A., & Haque, M. A. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103804
Cellular Senescence in Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Targeting
Liu, W., Gao, J., Zhang, X., Yang, F., Jiao, M., Chang, J., Su, L., & Li, X. (2026) · Advances in Ophthalmology Practice and Research · doi:10.1016/j.aopr.2026.07.002
Cassotti, I., Fiume, V., Gandellini, P., & Storlazzi, C. T. (2026) · Biomarker Research · doi:10.1186/s40364-026-00991-3
Metadata
- Authors
- Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., Dive, C., Enschede, S. H., Nolan, C., Chiu, Y.-L., Busman, T., Xiong, H., Krivoshik, A. P., Humerickhouse, R., Shapiro, G. I., & Rudin, C. M.
- Affiliations
- Rush University Medical Center (US)
- From the Dana-Farber Cancer Institute, Boston, MA; University of Colorado Cancer Center, Aurora, CO; Northwest Medical Specialties, Tacoma, WA; Rush University Medical Center, Chicago; Abbott Laboratories, Abbott Park, IL; University of California Davis Cancer Center, Sacramento, CA; Sunterra Oncology Associates, Phoenix, AZ; Johns Hopkins University, Baltimore, MD; and Paterson Institute for Cancer Research, University of Manchester, United Kingdom.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2011-03-01
- Volume
- 29
- Issue
- 7
- Pages
- 909-916
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- PMC
- PMC4668282
- OpenAlex
- W2119316461
- Cited by
- 603
- References
- 39
- Citations by year
- 2026: 35 · 2025: 28 · 2024: 30 · 2023: 34 · 2022: 32 · 2021: 37 · 2020: 39 · 2019: 29 · 2018: 33 · 2017: 31 · 2016: 40 · 2015: 46 · 2014: 57 · 2013: 54 · 2012: 51
- FWCI
- 24.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- navitoclax, BCL-2 inhibitor, small cell lung cancer, bronchial carcinoid, thrombocytopenia, progastrin-releasing peptide, apoptosis resistance, pharmacokinetics, safety and tolerability, intermittent dosing, continuous dosing, surrogate markers
- MeSH terms
- Administration, Oral, Aged, Aged, 80 and over, Aniline Compounds, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasms, Prognosis, Sulfonamides, Survival Analysis, Treatment Outcome, Risk Assessment, Genes, bcl-2, Maximum Tolerated Dose, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
